Eli Lilly’s oral weight-loss drug Foundayo fell short of market expectations in its second full quarter on the market. The company, however, stressed that once the initial distribution inventory effect is stripped out, actual U.S. demand more than tripled in a single quarter — a sign that demand is far from cooling.

In its third-quarter earnings release on Oct. 29 (local time), Lilly reported Foundayo revenue of $184 million (~250 billion won). That is an 88% increase from $98 million (~130 billion won) in the second quarter, immediately after U.S. Food and Drug Administration (FDA) approval, but it falls about $33 million (~44 billion won) short of the $217 million (~290 billion won) analyst consensus.

The company pointed to inventory sitting in distribution channels at launch as the reason for the revenue gap. In an interview with Reuters, Lilly Chief Financial Officer Lucas Montarce said roughly $30 million (~40 billion won) of second-quarter revenue represented initial inventory sold to wholesalers and pharmacies. That volume, which analysts had difficulty detecting, was booked in the second quarter, causing market forecasts to be set higher than actual demand, he said.

On a like-for-like basis, the picture changes. Montarce said U.S. demand excluding inventory more than tripled, from about $37 million (~50 billion won) in the second quarter to more than $120 million (~160 billion won) in the third quarter.

Prescription metrics also support the upward trend. According to market research firm IQVIA, weekly Foundayo prescriptions totaled 63,110 in the Oct. 26–30 period, roughly nine times the just-over 7,000 recorded in the fourth week after launch. In early October, weekly prescriptions climbed to a record 64,268.

New patient inflows have also accelerated. Lilly said the number of new Foundayo patients doubled in the third quarter from the prior quarter, and that about four out of every 10 U.S. patients newly starting an oral weight-loss drug are choosing Foundayo.

Still, the gap with frontrunner Novo Nordisk’s Wegovy pill remains wide. According to estimates from investment bank Jefferies, as of mid-October Lilly held about 25% of oral GLP-1 prescription share versus about 75% for Novo. Based on IQVIA data, Wegovy pill prescriptions totaled about 183,000 in the Oct. 26–30 week — three times those of Foundayo.

ItemFoundayo (Lilly)Wegovy pill (Novo Nordisk)Q3 revenue$184 million—Weekly prescriptions (Oct. 26–30)63,110~183,000Oral GLP-1 prescription share (mid-October)~25%~75%

Note: Prescription figures from IQVIA; share estimates from Jefferies.

The next test for Foundayo is fourth-quarter results. The key question is whether rising demand translates into higher revenue. Lilly also expects an FDA decision during the fourth quarter on a type 2 diabetes indication.

Outside the U.S., sales have begun in four countries including the U.K., and additional regulatory reviews are under way in more than 40 countries. A final approval from the European Commission expected around year-end would allow sales to expand into major European markets. The European Medicines Agency (EMA) recommended in early October that Foundayo be granted EU marketing authorization for adult weight management and treatment of type 2 diabetes.

Meanwhile, Lilly’s total third-quarter revenue rose 39% year over year to $24.397 billion (~32.8 trillion won), while net income increased 16% to $6.451 billion (~8.7 trillion won). The growth was driven by injectable diabetes treatment Mounjaro and weight-loss drug Zepbound, whose combined sales reached about $16.07 billion (~21.6 trillion won).

The oral weight-loss drug market is in an early phase of prescriptions shifting from injectables to pills. Foundayo still trails the Wegovy pill significantly on revenue metrics, but analysts say the pace of prescription growth and the rate of new patient inflows have laid the groundwork for a chase. Fourth-quarter revenue is expected to be the first quarter that confirms actual demand without the inventory effect.